Showing 4661-4670 of 6036 results for "".
- EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwanhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-expanded-license-agreement-with-betta-pharmaceuticals-for-eyp-1901-in-china-hong-kong-macau-and-taiwan/2480838/EyePoint Pharmaceuticals announced the execution of a license agreement with Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan. This agreement expands the collaboration between EyePoint and Equinox Sciences, a Bet
- C. Light Technologies Announces Activities and New Partnerships at ARVOhttps://modernod.com/news/c-light-technologies-announces-activities-and-new-partnerships-at-arvo/2480821/At this year’s Association for Research in Vision and Ophthalmology (ARVO), C. Light Technologies will meet with colleagues at booth #2424 to share engineering and software development updates from their new pipeline instrument,
- Opthea Presenting Clinical Data at ARVO 2022 Annual Meetinghttps://modernod.com/news/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting/2480820/Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022. Jason Slakter, MD, of
- Heidelberg Engineering Presents Various Scientific Innovations at ARVOhttps://modernod.com/news/heidelberg-engineering-presents-various-scientific-innovations-at-arvo/2480819/Heidelberg Engineering showcases its research capabilities at this year’s ARVO congress that takes place in Denver, Colorado, USA, from May 1–4. The team looks forward to reconnecting with the global research community after 2 years of solely virtual ARVO meetings, and to demonstratin
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i
- New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at ARVOhttps://modernod.com/news/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-to-be-presented-at-arvo/2480815/Opus Genetics announced that data from two preclinical studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5 or RDH12 genes, respectively, will b
- Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During ARVOhttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo/2480814/Bausch + Lomb announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colorado, from May 1-4, 2022, and virtually from May 11-12, 2022. The presentations incl
- Recent Alimera Data Featured in Scientific Programming at ARVOhttps://modernod.com/news/recent-alimera-data-featured-in-scientific-programming-at-arvo/2480813/Alimera Sciences announced today that Iluvien will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.
- Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission of Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-of-nyxol-for-reversal-of-mydriasis/2480812/Ocuphire Pharma announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). The results demonstrated that Nyxol’s efficacy and safety in pediatric subjects 3-11 ye
- Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meetinghttps://modernod.com/news/graybug-to-present-preclinical-data-for-gb-401-in-primary-open-angle-glaucoma-at-the-2022-arvo-annual-meeting/2480808/Graybug Vision announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 20